REGN5381 + Placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Uncontrolled Hypertension
Conditions
Uncontrolled Hypertension
Trial Timeline
Apr 16, 2025 → Oct 15, 2025
NCT ID
NCT06833190About REGN5381 + Placebo
REGN5381 + Placebo is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Uncontrolled Hypertension. The current trial status is terminated. This product is registered under clinical trial identifier NCT06833190. Target conditions include Uncontrolled Hypertension.
What happened to similar drugs?
4 of 11 similar drugs in Uncontrolled Hypertension were approved
Approved (4) Terminated (0) Active (7)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06833190 | Phase 2 | Terminated |
| NCT06237309 | Phase 2 | Terminated |
Competing Products
17 competing products in Uncontrolled Hypertension
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KHK4563 + KHK4563 + KHK4563 + Placebo | Kyowa Kirin | Phase 2 | 35 |
| HR17031 injection + insulin glargine | Jiangsu Hengrui Medicine | Phase 3 | 40 |
| Baxdrostat + Placebo | AstraZeneca | Phase 3 | 44 |
| Tralokinumab | AstraZeneca | Phase 3 | 40 |
| Baxdrostat + Placebo | AstraZeneca | Phase 3 | 40 |
| Benralizumab | AstraZeneca | Phase 3 | 40 |
| Baxdrostat + Placebo | AstraZeneca | Phase 2 | 35 |
| Experimental: Tralokinumab | AstraZeneca | Phase 3 | 40 |
| Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment E | AstraZeneca | Phase 1 | 29 |
| CIN-107 + Placebo | AstraZeneca | Phase 2 | 35 |
| Pegloticase + Methotrexate (MTX) | Amgen | Approved | 43 |
| Pegloticase | Amgen | Approved | 43 |
| Pegloticase + Methotrexate | Amgen | Phase 3 | 47 |
| Pegloticase + Methotrexate (MTX) | Amgen | Approved | 43 |
| Pegloticase with MTX | Amgen | Approved | 43 |
| abrocitinib | Pfizer | Pre-clinical | 30 |
| SAL0140 + SAL0140 placebo | Shenzhen Salubris Pharmaceuticals | Phase 1 | 36 |